1445796-56-4

Basic information

• Product Name: 2-fluoro-5-(3,4,5-trifluorophenylcarbamoyl)benzene-1-sulfonyl chloride
• Synonyms: 2-fluoro-5-(3,4,5-trifluorophenylcarbamoyl)benzene-1-sulfonyl chloride
• CAS NO: 1445796-56-4
• Molecular Weight: 367.708
• Mol File: 1445796-56-4.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 2-fluoro-5-(3,4,5-trifluorophenylcarbamoyl)benzene-1-sulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-fluoro-5-(3,4,5-trifluorophenylcarbamoyl)benzene-1-sulfonyl chloride(1445796-56-4)
• EPA Substance Registry System: 2-fluoro-5-(3,4,5-trifluorophenylcarbamoyl)benzene-1-sulfonyl chloride(1445796-56-4)

Safety Data

• Hazardous Substances Data: 1445796-56-4(Hazardous Substances Data)

Upstream product

• 456-22-4 4-Fluorobenzoic acid 
• 2267-40-5 3-chlorosulfonyl-4-fluoro-benzoic acid 
• 671-93-2 3-(chlorosulfonyl)-4-fluorobenzoyl chloride 
• 163733-96-8 3,4,5-trifluoro aniline 

Downstream Products

• 1445790-55-5 4-fluoranyl-3-(4-oxidanylpiperidin-1-yl)sulfonyl-N-[3,4,5-tris(fluoranyl)phenyl]benzamide 
• 1445790-79-3 C₁₇H₁₄F₄N₂O₄S 
• 1445790-84-0 C₁₉H₁₈F₄N₂O₅S 

Relevant articles and documents

Design, synthesis and anti-HBV activity of NVR3-778 derivatives

NVR3-778, one of the most advanced capsid assembly modulators (CAMs), is currently in phase II clinical trial for the treatment of HBV infection. In this study, we reported the first structure optimization of NVR3-778. Compound 2d was found to exhibit more potent anti-HBV activity (IC50: 0.25 μM), lower cytotoxicity (CC50: 10.68 μM) and higher selectivity index (SI: 40.72) than NVR3-778 (IC50: 0.33 μM; CC50: 5.14 μM; SI: 18.36) in vitro, and also display similar inhibitory effect on the assembly of HBV capsids as NVR3-778. Molecular docking further suggested that compound 2d might form a stronger interaction with core protein. Moreover, compound 2d also showed acceptable pharmacokinetic profiles. Currently compound 2d was selected as a new lead for further modifications, and studies to determine the in vivo anti-HBV studies of 2d will begin soon.

CYCLIC INHIBITORS OF HEPATITIS B VIRUS

The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.